News Center
-
Invest in Shanghai, Create the Future Together! Mr. Eric Tse Attends 2026 Shanghai Global Investment Promotion Conference, Deepening Coordinated Development of Sino Biopharmaceutical Limited in Shanghai and Jiangsu
On March 14, the 2026 Shanghai Global Investment Promotion Conference opened with a main promotion event at the Shanghai East International Business Cooperation Zone.View -
Ms. Theresa Tse Named to Forbes China List of Top 100 Outstanding Businesswomen in 2026, Leading the Leapfrog Development of Sino Biopharmaceutical Limited
On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation.View -
Sino Biopharmaceutical Limited Reaches Exclusive Licensing Agreement with Sanofi for Rovadicitinib
On March 4, Sino Biopharmaceutical Limited (1177.HK) announced that it has reached an exclusive licensing agreement with Sanofi for Rovadicitinib, a novel, potent, first-in-class (FIC) oral small-molecule JAK/ROCK inhibitor.View -
Benmelstobart's 4th Indication Approved for Marketing for Consolidation Therapy in Stage III Non-Small Cell Lung Cancer
On February 14, Benmelstobart Injection (Andewei®), a Class 1 new drug from CTTQ Pharma, a core enterprise of Sino Biopharmaceutical Limited (1177.HK), was approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) sensitizing mutations or anaplastic lymphoma kinase (ALK) rearrangements and whose disease has not progressed following platinum-based concurrent or sequential radiochemotherapy.View
Science for a healthier world
